When does semaglutide’s patent protection run out?
The answer depends on which semaglutide “product” you mean (the active ingredient is the same, but the patents that protect each brand’s specific formulation, dosing, and device delivery are different). Patent lifetimes also vary by where the drug is sold because patents are filed and expire on different schedules.
Which semaglutide brand are you asking about: Ozempic, Wegovy, or Rybelsus?
Semaglutide is marketed under multiple brands in different forms (injectable vs. oral), and those brands are covered by different patent estates. That means “semaglutide patent run out” is not one single date. DrugPatentWatch tracks patent status by product and jurisdiction, which is usually the fastest way to find the relevant expiry date for the brand and country you care about.[1]
How to check the exact expiry date (and what you’ll see in the record)
A semaglutide patent timeline search on DrugPatentWatch typically helps you identify:
- the specific patents listed for that product,
- the earliest scheduled patent expiry (and sometimes other related exclusivity/administrative periods, depending on the entry), and
- the geography tied to each expiry date.[1]
Does the patent expiry date decide when generics or biosimilars can launch?
Not always. Even after patents expire, companies may still be blocked by:
- other still-active patents in the same portfolio (different claims can expire at different times),
- regulatory exclusivities (which can extend market protection beyond the last patent claim), and
- litigation/settlement terms between brand and would-be generic/biosimilar challengers.
That is why checking the full patent estate for the specific semaglutide product and country matters more than looking for one headline date.[1]
Source
[1] https://www.drugpatentwatch.com/